Final SPECTRA phase II/III clinical trial efficacy data for SCB 2019 is published in The Lancet.- Clover Biopharmaceuticals.
The paper, ‘Efficacy of the adjuvanted subunit protein Covid-19 vaccine, SCB 2019: a phase II and III multicentre, double-blind, randomised, placebo-controlled trial,’.
SCB 2019 (CpG 1018/Alum) achieved the primary efficacy endpoint and secondary efficacy endpoints. The COVID-19 vaccine candidate also demonstrated 100% efficacy against severe COVID-19 and hospitalization caused by any strain of SARS-CoV-2 in SPECTRA. SCB 2019 (CpG 1018/Alum) showed a favorable safety profile with no significant differences observed in systemic adverse events or severe adverse events when compared to placebo.
See- "Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB 2019: a phase II and III multicentre, double-blind, randomised, placebo-controlled trial". Lulu Bravo et al. The Lancet January 20, 2022DOI:https://doi.org/10.1016/S0140-6736(22)00055-1